They may even contain ingredients not listed
Some people choose this approach, hoping to minimize side effects while still getting benefits for weight loss or blood sugar control
The industry is racing to figure out the effects of GLP-1 agonists on different conditions and populations and to test for secondary indications to treat cardiovascular diseases and liver disorders
Research on semaglutide and liraglutide has documented menstrual cycle changes associated with significant weight reduction
To help fill this gap, the researchers looked back at hundreds of singleton pregnancies delivered in the Mass General Brigham health system between 2016 and 2025
No transdermal GLP-1 patch is approved by the Food and Drug Administration for weight loss, and that matters, because approval is what verifies a product actually contains what it claims, at the dose it claims, and does what it says